中国扩大免疫规划1974至2024年健康影响与经济评价:建模研究
本研究用数学模型评估中国扩大免疫规划(EPI)八种常规疫苗在1974至2024年间对八种病原体的健康与经济影响。社会视角效益成本比为19.48,提供方视角为8.02。
核心结论
- 中国EPI在过去50年取得显著健康与经济成就,支持全球EPI成功;作者认为应进一步投资EPI以维持覆盖率并扩大疫苗纳入。
研究设计与样本
- 基于数据可及性和疾病负担,对八种常规疫苗针对八种病原体(麻疹、百日咳、乙型肝炎、结核病、甲型肝炎、流行性乙型脑炎、A群脑膜炎、脊髓灰质炎)进行数学建模,并特别考虑疫苗影响的非线性。
- 比较无接种反事实场景(疫苗覆盖率设为零)与当前接种场景(0至6岁常规接种),采用日历年法和出生队列法计算健康与经济结局。
主要发现
- 社会视角总效益成本比为19.48(18.82至22.08),提供方视角为8.02(7.64至8.80)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Expanded Program on Immunization (EPI), initiated by WHO in 1974, is a cornerstone of public health. China's EPI covers more than a sixth of the world's population and includes eight routine vaccines with high coverage rates. This study aimed to estimate health and economic impacts of China's EPI over the past 50 years (1974-2024). METHODS: This study mathematically modelled the impact of all eight routine vaccines in China's EPI against eight pathogens (measles, pertussis, hepatitis B, tuberculosis, hepatitis A, Japanese encephalitis, meningitis A, and poliomyelitis) based on data availability and their substantial disease burden, particularly accounting for non-linearities in vaccine impact. Health and economic outcomes were determined using mathematical models between a counterfactual scenario without vaccination (vaccine coverage set to zero) and the current vaccination scenario (routine vaccination scheduled at age 0-6 years), based on calendar year and birth cohort approaches. The health impact of China's EPI from 1974 to 2024 was measured in the number of cases, deaths, and disability-adjusted life-years (DALYs) averted. FINDINGS: We estimated that China's EPI averted 703·02 million cases (95% credible interval 699·51-722·80) and 2·48 million deaths (2·14-2·97) in 1974-2024 based on the calendar year approach, equivalent to averting an estimated 160·22 million DALYs (145·05-196·99). Using the birth cohort approach, we predicted 707·41 million cases (703·93-727·03) and 7·01 million deaths (6·95-7·87) averted over the lifetime, corresponding to 279·02 million DALYs (265·78-316·12). From a societal perspective, the aggregated cost of vaccination was estimated to be US$124·06 billion (120·49-127·49), although the benefits amounted to $2417·85 billion (2359·38-2710·35). China's EPI yielded an aggregate benefit-cost ratio of 19·48 (18·82-22·08) from the societal perspective and 8·02 (7·64-8·80) from the provider's perspective. INTERPRETATION: China's EPI has shown remarkable health and economic achievements, contributing to worldwide EPI success in the past 50 years. Further investment in EPI is warranted to sustain coverage and expand vaccine inclusion in China and globally. FUNDING: Beijing Natural Science Foundation. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Wang C, Lai X, Abbas K, et al. Health impact and economic evaluation of the Expanded Program on Immunization in China from 1974 to 2024: a modelling study. Lancet Public Health. 2025. PMID: 40286808. doi:10.1016/S2468-2667(25)00039-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。